Periodic Reporting for period 1 - FGen (The NanoLiter Reactor sequencing -- Quick and cost-effective method to develop microbial strains)
Reporting period: 2019-05-01 to 2019-08-31
In the carried-out Phase 1 project we evaluated the application of FGen’s proprietary technology that facilitates and accelerates strain development for bio-based production and identified products that currently suffer from efficient production strains.
In the second part of the project we elaborated a business plan for the implementation of the strain development program and for the establishment of a manufacturing process, which can be carried out either with a contract manufacturing organization (CMO) or with an industrial partner. We calculated a financing requirement of ~3.5 million Euro to develop the production strain and the corresponding bioprocess including pilot-production for the first two years. FGen will generate product sales from the third year on and reach break-even latest after five years based on product sales of 6 and 30 million in the worst- and best-case scenario, respectively. This increase in turnover enables FGen the generation of 20 to 100 full time positions and the development of additional sustainable bio-based production processes.